





Submitted by: Chief Medical Officer
 Name: Johnathan Lancaster, MD, PhD
 Company/Organization: Myriad Genetic Laboratories, Inc.
 Address: 320 Wakara Way, Salt Lake City, UT 84108
 Phone: 801-505-5090
 Email: jlancaster@myriad.com
 Date of request: July 6, 2018
 NCCN Guidelines Panel: Breast Cancer


Specific Changes: On page BINV-J:



Add footnote: The 12-gene recurrence test (EndoPredict from Myriad Genetics) can be used to identify women with a low risk of recurrence in the 5-10 year range that may be spared endocrine therapy beyond 5 years.

Rationale: Clinical uncertainty still exists around the benefit of extended endocrine therapy among women with early stage, ER+, HER- breast cancer. In two studies, EndoPredict has been shown identify patients with a very low risk of recurrence (1.8-4.3%) in the 5-10 year time frame^{1,2} who are therefore unlikely to benefit in a clinically meaningful way from extended endocrine therapy.





References

1. Dubsky P, Brase J, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. *British Journal of Cancer* **2013** 109(12):2959-64.
2. Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer. *JAMA Oncology* **2018**;4(4):545-553.

Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer
Myriad Genetic Laboratories Inc.